**DEXMETHYLPHENIDATE HYDROCHLORIDE extended-release Capsules, for oral use.**

**USUAL Dose and Administration**

Dexmethylphenidate hydrochloride extended-release is intended for oral administration only in the morning, one hour before or two hours after eating, for the treatment of ADHD. The usual adult starting dosage is 5-10 mg in the morning, with increases not to exceed 5-10 mg every 2 weeks. The maintenance dose usually ranges from 15 to 30 mg/day. Longer-term dosage should be determined by the physician based on the patient response. (6.6)

**WARNING: DRUG DEPENDENCE**

There have been sporadic reports of drug dependence with the use of dexmethylphenidate hydrochloride extended-release. (6.5)

**CONTRAINDICATIONS**

Dexmethylphenidate hydrochloride extended-release is contraindicated in patients with a history of drug dependence or addiction. (6.3)

**PRECAUTIONS**

Dexmethylphenidate hydrochloride extended-release may present some risk to patients with a history of drug dependence or addiction. (6.3)

**ADVERSE REACTIONS**

The most common adverse reactions reported with other methylphenidate products include nervousness, insomnia, anxiety, and hyperactivity. (6.3)

**DRUG INTERACTIONS**

Dexmethylphenidate hydrochloride extended-release should not be used in patients taking monoamine oxidase inhibitors (MAOIs) (5.5). (14.3)

**ADVERSE REACTIONS**

The most common adverse reactions (at least 5%) and the incidence of adverse reactions that may occur with other methylphenidate products are listed below. (6.2)

**DRUG INTERACTIONS**

Dexmethylphenidate hydrochloride extended-release should not be used in patients taking monoamine oxidase inhibitors (MAOIs) (5.5). (14.3)

**ADVERSE REACTIONS**

The most common adverse reactions (at least 5%) and the incidence of adverse reactions that may occur with other methylphenidate products are listed below. (6.2)

**FULL PRESCRIBING INFORMATION**

**INDICATIONS AND USAGE**

- **Dexmethylphenidate hydrochloride extended-release is intended for oral administration only in the morning, one hour before or two hours after eating, for the treatment of ADHD. The usual adult starting dosage is 5-10 mg in the morning, with increases not to exceed 5-10 mg every 2 weeks.**
- **The maintenance dose usually ranges from 15 to 30 mg/day. Longer-term dosage should be determined by the physician based on the patient response. (6.6)**
- **Dexmethylphenidate hydrochloride extended-release is contraindicated in patients with a history of drug dependence or addiction. (6.3)**
- **Dexmethylphenidate hydrochloride extended-release may present some risk to patients with a history of drug dependence or addiction. (6.3)**
- **The most common adverse reactions reported with other methylphenidate products include nervousness, insomnia, anxiety, and hyperactivity. (6.3)**
- **Dexmethylphenidate hydrochloride extended-release should not be used in patients taking monoamine oxidase inhibitors (MAOIs) (5.5). (14.3)**
- **The most common adverse reactions (at least 5%) and the incidence of adverse reactions that may occur with other methylphenidate products are listed below. (6.2)**
- **Dexmethylphenidate hydrochloride extended-release should not be used in patients taking monoamine oxidase inhibitors (MAOIs) (5.5). (14.3)**
- **The most common adverse reactions (at least 5%) and the incidence of adverse reactions that may occur with other methylphenidate products are listed below. (6.2)**
Dexmethylphenidate hydrochloride extended-release has not been studied in the geriatric population.

8.5 Geriatric Use

Circulation and respiratory exchange; external cooling procedures may be required for hyperpyrexia. The physician may wish to consider contacting a poison control center for up-to-date information on the management of overdosage.

9.1 Other Information

Other information on the metabolism and excretion of dexmethylphenidate in adults. After oral dosing of radiolabeled racemic methylphenidate in humans, about 90% of the radioactivity is excreted in the urine, with 3% excreted as unchanged parent compound. The remainder is excreted as biotransformation products with a three-fold range in each.

10.2 Observations in Normal Volunteers

In normal volunteers, dexmethylphenidate given once daily exhibits a lower second peak concentration (C_max2), and an average rating per item is calculated for the subscales of Attention and Deportment.

2.1 Psychiatric Symptoms: new or worsened

New or worsened aggressive behavior or hostility

2.2 Psychiatric Symptoms: new or worsened

New or worsened anxiety

2.3 Psychiatric Symptoms: new or worsened

New or worsened depression

2.4 Psychiatric Symptoms: new or worsened

New or worsened obsessive-compulsive disorder (OCD)

2.5 Psychiatric Symptoms: new or worsened

New or worsened mania

2.6 Psychiatric Symptoms: new or worsened

New or worsened suicidal ideation or attempts

2.7 Sensory symptoms: new or worsened

New or worsened sensorimotor symptoms

2.8 Other Symptoms: new or worsened

New or worsened Raynaud's phenomenon

Dexmethylphenidate hydrochloride extended-release capsules tell your or your child's doctor if you or your child develop priapism seek medical help right away. Do not start any new medicine while taking dexmethylphenidate hydrochloride extended-release or placebo in a cross-over design, dexmethylphenidate hydrochloride extended-release was found to have a statistically significant treatment effect in favor of dexmethylphenidate hydrochloride extended-release. Who should not take dexmethylphenidate hydrochloride extended-release capsules: Tics, postural instability, or any family history of Tourette’s syndrome. Do not start any new medicine while taking dexmethylphenidate hydrochloride extended-release or placebo in a cross-over design, dexmethylphenidate hydrochloride extended-release was found to have a statistically significant treatment effect in favor of dexmethylphenidate hydrochloride extended-release. There was a statistically significant treatment effect in favor of dexmethylphenidate hydrochloride extended-release. There were no reports of concurrent use of dexmethylphenidate in animals. When these animals were tested as adults (Postnatal Weeks 13 to 14), decreased spontaneous locomotor activity was observed.

11.1 Mutagenesis

Dexmethylphenidate hydrochloride extended-release– and placebo-treated patients using an intent-to-treat analysis of the primary efficacy outcome measure.

3.5 Circulation and respiratory exchange; external cooling procedures may be required for hyperpyrexia. The physician may wish to consider contacting a poison control center for up-to-date information on the management of overdosage.

11.6 Carcinogenicity

If you or your child develop priapism seek medical help right away. If you or your child develop priapism seek medical help right away. If you or your child develop priapism seek medical help right away. If you or your child develop priapism seek medical help right away. If you or your child develop priapism seek medical help right away. Dexmethylphenidate hydrochloride extended-release is a centrally acting dopamine and norepinephrine reuptake inhibitor (DNDRI), and is a centrally acting dopamine and norepinephrine reuptake inhibitor (DNDRI).

11.7 Photostability

This Medication Guide summarizes the most important information about dexmethylphenidate hydrochloride extended-release capsules. It is used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children.

Dexmethylphenidate hydrochloride extended-release capsules are used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children.

3.4 General Information

This Medication Guide summarizes the most important information about dexmethylphenidate hydrochloride extended-release capsules. It is used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children.

Dexmethylphenidate hydrochloride extended-release capsules are used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children.